Drug Trial Radar · NCT07173478
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
Conditions
- Atopic Dermatitis (AD)
Interventions
OPA-15406Drug
1% foam, topical, twice daily, for 4 weeks
VehicleDrug
vehicle, topical, twice daily, for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success rate in Investigator's Global Assessment (IGA)Time frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mita Dermatology Clinic
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.